INBS Seeks Shareholder Approval for Reverse Split, Warrant Issuance

TL;DR

**INBS is gearing up for a reverse stock split and massive warrant issuance, signaling potential dilution and a desperate attempt to maintain Nasdaq compliance, even if they claim it's 'precautionary.'**

AI Summary

Intelligent Bio Solutions Inc. (INBS) is holding its Annual Meeting on October 16, 2025, to address several critical proposals impacting its capital structure and governance. Key proposals include the election of four directors, ratification of UHY LLP as the independent auditor for fiscal year ending June 30, 2026, and a significant amendment to the 2019 Long Term Incentive Plan, increasing the shares available by 495,000 to a total of 1,795,000 shares. The company also seeks approval for the issuance of up to 4,147,616 shares of common stock related to a Warrant Inducement Transaction and placement agent warrants, which collectively represent 20% or more of outstanding common stock. Furthermore, INBS is proposing a reverse stock split at a ratio of 1-for-2 to 1-for-10 as a precautionary measure to maintain Nasdaq Capital Market minimum bid price compliance, despite currently being in compliance. The filing does not provide specific revenue or net income figures, focusing instead on corporate actions and shareholder voting matters.

Why It Matters

This DEF 14A filing is crucial for INBS investors as it outlines significant capital structure changes, including a potential reverse stock split and substantial warrant issuances, which could impact share price and ownership dilution. The proposed increase in the 2019 Long Term Incentive Plan by 495,000 shares could dilute existing shareholder value but may also incentivize key employees. For the broader market, INBS's proactive reverse stock split proposal, even while compliant with Nasdaq, highlights ongoing concerns for micro-cap companies regarding listing standards and capital market access, setting a precedent for similar firms in competitive biotech sectors.

Risk Assessment

Risk Level: high — The proposal to issue up to 4,147,616 shares of common stock underlying warrants, representing 20% or more of common stock outstanding, indicates significant potential dilution for existing shareholders. Additionally, the request for a reverse stock split at a ratio of 1-for-2 to 1-for-10, even if precautionary, suggests underlying concerns about future stock price stability and Nasdaq compliance, which could erode investor confidence.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the proposed warrant exercise and the implications of a reverse stock split on share liquidity and market perception. Consider voting against the warrant exercise and reverse stock split proposals if you are concerned about immediate dilution and the long-term value of your holdings.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

N/A

cash Position

$0

revenue Growth

N/A

Key Numbers

• 495,000 shares — Increase in 2019 Long Term Incentive Plan (Proposed additional shares for the incentive plan, bringing the total to 1,795,000 shares)
• 1,795,000 shares — Aggregate shares in 2019 Long Term Incentive Plan (Total shares if Proposal 3 is approved, up from 1,300,000 shares)
• 4,147,616 shares — Maximum shares underlying warrants (Proposed issuance for Warrant Inducement Transaction and placement agent, representing 20% or more of outstanding common stock)
• 4,046,456 shares — Shares from Series J common stock purchase warrants (Part of the Warrant Inducement Transaction)
• 101,160 shares — Shares from placement agent warrants (Part of the Warrant Inducement Transaction)
• 1-for-2 — Minimum reverse stock split ratio (Proposed minimum ratio for the reverse stock split)
• 1-for-10 — Maximum reverse stock split ratio (Proposed maximum ratio for the reverse stock split)
• 9,028,712 shares — Issued and outstanding common stock (Shares entitled to vote as of the Record Date, September 11, 2025)
• 20% — Threshold for Nasdaq Listing Rule 5635(d) (The warrant issuance exceeds this threshold, requiring shareholder approval)
• 12 months — Timeframe for reverse stock split (Period within which the Board can effect a reverse stock split after stockholder approval)

Key Players & Entities

• Intelligent Bio Solutions Inc. (company) — Registrant and company holding the Annual Meeting
• Steven Boyages (person) — Chairman of the Board of Directors
• Harry Simeonidis (person) — President and Chief Executive Officer
• UHY LLP (company) — Independent registered public accounting firm
• Nasdaq Capital Market (regulator) — Stock exchange with minimum bid price requirements
• Continental Stock Transfer and Trust Company (company) — Transfer agent for INBS
• Alliance Advisors, LLC (company) — Proxy solicitor for INBS
• July 25, 2025 (date) — Date of warrant exercise inducement offer letters
• October 16, 2025 (date) — Date of the Annual Meeting of Stockholders
• September 11, 2025 (date) — Record Date for stockholders entitled to vote

FAQ

Risk Factors

• Nasdaq Listing Compliance [high — regulatory]: The proposed issuance of up to 4,147,616 shares for the Warrant Inducement Transaction and placement agent warrants represents 20% or more of the outstanding common stock. This triggers Nasdaq Listing Rule 5635(d), requiring shareholder approval to avoid potential delisting.
• Reverse Stock Split Necessity [medium — financial]: The company is proposing a reverse stock split (1-for-2 to 1-for-10) as a precautionary measure to maintain compliance with the Nasdaq Capital Market minimum bid price requirement. While currently in compliance, failure to maintain this could lead to delisting.
• Dilution from Warrant Issuance [medium — financial]: The potential issuance of 4,147,616 shares related to warrant exercises and placement agents could significantly dilute existing shareholders. This represents a substantial portion of the 9,028,712 shares outstanding as of the Record Date.
• Incentive Plan Share Increase [low — operational]: The proposed amendment to the 2019 Long Term Incentive Plan seeks to increase the available shares by 495,000, bringing the total to 1,795,000. This could lead to further dilution if these options or awards are exercised.

Industry Context

Intelligent Bio Solutions Inc. operates in the biotechnology and diagnostics sector, a field characterized by rapid innovation, significant R&D investment, and stringent regulatory oversight. Companies in this space often face challenges in scaling operations, securing funding, and navigating complex approval processes for new products. The competitive landscape includes both established players and emerging startups, making market positioning and strategic financing crucial for survival and growth.

Regulatory Implications

The company faces direct regulatory scrutiny from the Nasdaq Stock Market regarding its listing requirements, particularly the minimum bid price. Failure to maintain compliance could lead to delisting. Additionally, any equity issuances must adhere to securities laws and exchange rules, with significant issuances requiring shareholder approval to prevent undue dilution and ensure corporate governance standards are met.

What Investors Should Do

1. Review the proposed Warrant Inducement Transaction and placement agent warrants (Proposal 4).
2. Evaluate the necessity and potential impact of the proposed Reverse Stock Split (Proposal 5).
3. Consider the proposed increase in shares for the 2019 Long Term Incentive Plan (Proposal 3).
4. Vote on the ratification of UHY LLP as the independent auditor (Proposal 2).

Key Dates

• 2025-10-16: Annual Meeting of Stockholders — Key proposals regarding capital structure, governance, and Nasdaq compliance will be voted upon.
• 2025-09-11: Record Date for Annual Meeting — Establishes the list of shareholders entitled to vote at the Annual Meeting.
• 2025-09-19: Mailing of Proxy Statement — Shareholders receive the official proxy materials to review before the meeting.
• 2025-10-15: Deadline to Register for Virtual Meeting — Shareholders must register by this date to receive the link and password to attend the virtual meeting.

Glossary

DEF 14A

A proxy statement filing required by the SEC for companies holding annual meetings, detailing information about the meeting and the proposals to be voted on. (This document is the primary source of information for the INBS annual meeting and its proposals.)

Warrant Inducement Transaction

A transaction where a company offers incentives, typically in the form of additional warrants or stock, to encourage holders of existing warrants to exercise them. (INBS is seeking approval for a large share issuance related to such a transaction, which could significantly impact share count.)

Placement Agent Warrants

Warrants issued to the agents who helped facilitate a securities offering, as compensation for their services. (These are part of the proposed share issuance requiring shareholder approval due to their size.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (INBS is proposing this to maintain compliance with Nasdaq's minimum bid price rule.)

Nasdaq Capital Market

A tier of the Nasdaq stock market for smaller companies that have less stringent listing requirements than the Global Select or Global Market tiers. (INBS aims to maintain its listing on this market, necessitating compliance with its bid price rules.)

2019 Long Term Incentive Plan

A plan established by the company to grant equity-based compensation (like stock options or restricted stock) to employees and directors to incentivize long-term performance. (The company is seeking to increase the number of shares available under this plan.)

Year-Over-Year Comparison

This filing focuses on upcoming corporate actions and does not provide comparative financial data from a previous fiscal year's 10-K or proxy statement. Key metrics like revenue, net income, and margins are not disclosed in this DEF 14A. The primary focus is on proposals requiring shareholder approval, such as warrant issuances and a reverse stock split, which are new strategic and financial maneuvers rather than year-over-year performance changes.

Filing Documents

• formdef14a.htm (DEF 14A) — 734KB
• formdef14a_001.jpg (GRAPHIC) — 31KB
• proxy_001.jpg (GRAPHIC) — 426KB
• proxy_002.jpg (GRAPHIC) — 488KB
• 0001493152-25-014245.txt ( ) — 3587KB
• inbs-20250630.xsd (EX-101.SCH) — 3KB
• inbs-20250630_def.xml (EX-101.DEF) — 5KB
• inbs-20250630_lab.xml (EX-101.LAB) — 52KB
• inbs-20250630_pre.xml (EX-101.PRE) — 38KB
• formdef14a_htm.xml (XML) — 6KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 22 Director Independence 23 Related Party Transactions 23 Audit Committee Report 25 Proposal 1 : Election of Directors 26 Proposal 2 : Auditor Ratification Proposal. 27 Proposal 3 : 2019 Plan Amendment Proposal 28 Proposal 4 : Warrant Exercise Proposal 33 Proposal 5 : Reverse Stock Split Proposal 36 Proposal 6 : Adjournment Proposal Related to Warrant Exercise Proposal 45 Proposal 7 : Adjournment Proposal Related to Reverse Stock Split Proposal 46 Availability of Annual Report on Form 10-K 47 Other Proposed Action 47 Householding of Proxy Materials 47 Stockholder Proposals and Submissions 47 Annex A - 2019 Long Term Incentive Plan, as amended and restated A-1 Annex B – Certificate of Amendment B-1 I INTELLIGENT BIO SOLUTIONS INC. 135 West, 41st Street, 5th Floor, New York, NY 10036 PROXY FOR ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 16, 2025 INFORMATION ABOUT THE ANNUAL MEETING AND VOTING WHY DID YOU SEND ME THIS PROXY STATEMENT? This proxy statement and the enclosed proxy card are furnished in connection with the solicitation of proxies by the Board of Directors (the "Board") of Intelligent Bio Solutions Inc., a Delaware corporation ("INBS," the "Company," "we," or "our"), for use at the virtual annual meeting of the Company's stockholders for the fiscal year ended June 30, 2024 (the "Annual Meeting"), to be held on October 16, 2025, at 3:30 p.m. Eastern Time, and at any adjournments or postponements thereof. In order to attend the meeting virtually, you must first register at https://web.viewproxy.com/inbs/2025AM2 by 11:59p.m. Eastern Time on October 15, 2025. After registering, you will receive an e-mail containing a unique link and password that will enable you to attend the meeting and vote at the meeting and at any adjournment or postponement thereof. You will not be able to attend the Annual Meeting in person

View Full Filing

View this DEF 14A filing on SEC EDGAR